Business Context and Reporting Period
This Form 10-Q covers the quarterly and six-month periods ended June 30, 1996, for Schering-Plough Corporation. The registrant is a pharmaceutical and healthcare products company incorporated in New Jersey. As of June 30, 1996, there were 369,678,128 common shares outstanding.
Key Financial Metrics
| Metric (Dollars in millions) | Three Months Ended June 30, 1996 | Six Months Ended June 30, 1996 |
|---|---|---|
| Sales | $1,476.6 | $2,859.3 |
| Income from Continuing Operations | $317.1 | $643.7 |
| Net Income | $317.1 | $643.7 |
| Earnings Per Share (Continuing Ops) | $0.86 | $1.75 |
| Operating Cash Flow (6 months) | $676.1 | |
| Cash and Cash Equivalents (End of Period) | $497.6 | |
| Total Debt (Short-term + Long-term) | $764.8 | |
| Cost of Sales Margin | 19.4% | 19.2% |
| Effective Tax Rate | 24.5% | 24.5% |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated sales increased 11% ($144.1 million) for the quarter and 12% ($302.6 million) for the six months compared to 1995. Excluding foreign currency effects, growth was 13% and 12% respectively.
- Profitability: Income before taxes from continuing operations rose 15% for both the quarter and six months. Earnings per share from continuing operations increased 16% to $0.86 (quarter) and $1.75 (six months).
- Product Performance:
- Respiratory: Sales grew 29% (quarter) and 26% (six months), driven by CLARITIN market share gains, partially offset by generic competition for PROVENTIL.
- Cardiovascular: U.S. sales rose 30% (quarter) and 33% (six months) due to IMDUR and NITRO-DUR.
- Anti-infective/Anticancer: Sales grew 14% (quarter) and 36% (six months), aided by INTRON-A and the launch of CEDAX.
- Health Care Products: Sales declined 3% (quarter) and 4% (six months), with over-the-counter products down 27% due to competition and pricing.
- Discontinued Operations: The prior year (1995) included a significant loss on disposal of discontinued operations ($156.2 million), which did not recur in 1996, contributing to the year-over-year net income increase.
Guidance, Outlook, and Risks
- Outlook: Management anticipates total research and development expenses to approximate $720 million for the full year 1996. The company expects continued negative effects on PROVENTIL sales and profitability due to generic metered-dose inhaler competition.
- Market Risks: The company faces increasing competitive pricing pressure from managed care and government cost-containment programs globally. Future effects of health care initiatives on operations and cash flows cannot be reasonably estimated.
- Legal Contingencies:
- Antitrust: The company is a defendant in over 150 antitrust actions. A federal class action settlement of $22.1 million (payable over three years) was approved on June 21, 1996. Other state and federal cases remain pending, with plaintiffs seeking treble damages.
- Product Liability: Subsidiaries are defendants in lawsuits involving approximately 500 plaintiffs regarding synthetic estrogens. Management believes recorded liabilities are not material and that additional material liability is remote.
- Liquidity: Cash generated from operations ($676.1 million for six months) funded dividends ($227.8 million), capital expenditures ($125.9 million), and debt repayments ($100.0 million long-term, $59.1 million short-term). A $500 million share repurchase program was completed in the second quarter.
Investor Verification Checklist
- Verify the impact of generic competition on the PROVENTIL product line and the offsetting performance of the Warrick Pharmaceuticals generic inhaler.
- Confirm the status and potential financial exposure of the remaining 150+ antitrust actions beyond the settled federal class action.
- Monitor the effectiveness of cost-containment measures in international markets and their impact on future revenue growth.
- Review the progress of the $720 million R&D budget and the pipeline for new product launches to sustain growth.
- Assess the sustainability of the 19.2% cost of sales ratio given the changing product mix and competitive pricing environment.